Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ETBX-021

Vaccine (Adenoviral vector) · Immune activation, directed at HER2 (ERBB2) · developed by ImmunityBio

Phase 1/2 Most advanced trial (none active)

IBRX Developer

1 Registered trials

What is ETBX-021?

ETBX-021 is a replication-defective adenovirus serotype 5 vaccine encoding HER2, designed to induce cytotoxic T-lymphocyte responses against HER2-expressing tumor cells. It is studied in head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Adenoviral vector)
Targets: HER2 (ERBB2) (antigen)
Mechanism: Immune activation, directed at HER2 (ERBB2)
Pathways: immune_activation
Therapy area: Oncology
Developer: ImmunityBio, Inc. (IBRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: S4MK9TOL0D

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03169764	Phase 1/2	Head and Neck Squamous Cell Carcinoma	Withdrawn	IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Head and Neck Squamous Cell Carcinoma

Other drugs acting on ERBB2

Neratinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved ADCT-502 Phase 1 BH-30643 Phase 1/2 CGT4255 Phase 1 CUDC-101 Phase 1 ELVN-002 Phase 1 Enozertinib Phase 1/2 NVL-330 Phase 1 TTX-MC138 Phase 1/2

More from ImmunityBio

Nogapendekin Alfa Inbakicept FDA approved 5Fluorouracil Phase 2 AAHI-SC2 Phase 1/2 AAHI-SC3 Phase 1/2 Adenoviral Vector Ad5-CEA Vaccine Phase 1/2 agenT-797 Phase 3 Aldoxorubicin Phase 2 CD19 t-haNK Phase 2 ETBX-051 Phase 1/2 ETBX-061 Phase 1/2 ETBX-071 Phase 2 GI-4000 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the IBRX page.

Follow IBRX, the company behind ETBX-021

See IBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IBRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z